Nassrin Payvandi

650 total citations
8 papers, 472 citations indexed

About

Nassrin Payvandi is a scholar working on Infectious Diseases, Toxicology and Pharmacology. According to data from OpenAlex, Nassrin Payvandi has authored 8 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Infectious Diseases, 3 papers in Toxicology and 2 papers in Pharmacology. Recurrent topics in Nassrin Payvandi's work include Pharmacovigilance and Adverse Drug Reactions (3 papers), HIV Research and Treatment (2 papers) and Statistical Methods in Clinical Trials (2 papers). Nassrin Payvandi is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (3 papers), HIV Research and Treatment (2 papers) and Statistical Methods in Clinical Trials (2 papers). Nassrin Payvandi collaborates with scholars based in United Kingdom, United States and Germany. Nassrin Payvandi's co-authors include Joan B. Soriano, George Visick, Hana Muellerova, Anna Hansell, David Fram, Nancy Yuen, Gregory Powell, John M. Fitzpatrick, William DuMouchel and June S. Almenoff and has published in prestigious journals such as CHEST Journal, Journal of Antimicrobial Chemotherapy and Regulatory Peptides.

In The Last Decade

Nassrin Payvandi

6 papers receiving 456 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nassrin Payvandi United Kingdom 4 389 183 74 57 29 8 472
Netsanet A. Negewo Australia 6 339 0.9× 195 1.1× 67 0.9× 32 0.6× 26 0.9× 9 458
Κonstantinos Bartziokas Greece 11 295 0.8× 165 0.9× 41 0.6× 50 0.9× 11 0.4× 39 450
Ann Morgan United Kingdom 10 346 0.9× 86 0.5× 67 0.9× 103 1.8× 28 1.0× 22 482
Nancy A. Morgan United States 5 539 1.4× 233 1.3× 75 1.0× 50 0.9× 15 0.5× 9 661
Paul Cascagnette Canada 5 181 0.5× 81 0.4× 41 0.6× 18 0.3× 33 1.1× 6 281
Susan Collier United Kingdom 7 141 0.4× 103 0.6× 28 0.4× 70 1.2× 40 1.4× 15 343
Francisco Javier Cabrera Spain 6 374 1.0× 62 0.3× 112 1.5× 61 1.1× 31 1.1× 6 412
Melissa Clarke Australia 6 297 0.8× 209 1.1× 19 0.3× 14 0.2× 19 0.7× 7 437
Frank Barnhart United States 7 1.2k 3.2× 900 4.9× 56 0.8× 38 0.7× 25 0.9× 15 1.3k
Lucy Frith United Kingdom 10 711 1.8× 570 3.1× 19 0.3× 21 0.4× 24 0.8× 18 815

Countries citing papers authored by Nassrin Payvandi

Since Specialization
Citations

This map shows the geographic impact of Nassrin Payvandi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nassrin Payvandi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nassrin Payvandi more than expected).

Fields of papers citing papers by Nassrin Payvandi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nassrin Payvandi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nassrin Payvandi. The network helps show where Nassrin Payvandi may publish in the future.

Co-authorship network of co-authors of Nassrin Payvandi

This figure shows the co-authorship network connecting the top 25 collaborators of Nassrin Payvandi. A scholar is included among the top collaborators of Nassrin Payvandi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nassrin Payvandi. Nassrin Payvandi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Patel, Parul, Ana Milinkovic, Richard Grove, et al.. (2025). Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks. Journal of Antimicrobial Chemotherapy. 80(9). 2375–2383.
2.
Vannappagari, Vani, Scott McCallister, Mark Bush, et al.. (2024). Responding to the Call to Action: Framework to Accelerate Clinical Data Generation for Antiretroviral Use in Pregnant Individuals with HIV. Infectious Diseases and Therapy. 13(7). 1391–1398. 3 indexed citations
3.
Wohlfeiler, Michael, Karam Mounzer, Laurence Brunet, et al.. (2020). Antiretroviral therapy and liver disorders in the OPERA® cohort. Therapeutic Advances in Drug Safety. 11. 585518905–585518905. 1 indexed citations
4.
DuMouchel, William, et al.. (2013). Automated Method for Detecting Increases in Frequency of Spontaneous Adverse Event Reports over Time. Journal of Biopharmaceutical Statistics. 23(1). 161–177. 5 indexed citations
5.
Lettis, Sally, et al.. (2008). Developing tools for the safety specification in risk management plans: lessons learned from a pilot project. Pharmacoepidemiology and Drug Safety. 17(5). 445–454. 2 indexed citations
6.
Almenoff, June S., Gregory Powell, David Fram, et al.. (2007). Online Signal Management: A Systems-Based Approach That Delivers New Analytical Capabilities and Operational Efficiency to the Practice of Pharmacovigilance. Drug Information Journal. 41(6). 779–789. 6 indexed citations
7.
Soriano, Joan B., George Visick, Hana Muellerova, Nassrin Payvandi, & Anna Hansell. (2005). Patterns of Comorbidities in Newly Diagnosed COPD and Asthma in Primary Care. CHEST Journal. 128(4). 2099–2107. 455 indexed citations
8.
Payvandi, Nassrin, et al.. (1988). Neuropeptide Y-mediated potentiation of vasoconstrictor responses in rat kidney. Regulatory Peptides. 22(4). 394–394.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Netsanet A. Negewo Breakdown of academic impact, for papers by Κonstantinos Bartziokas Breakdown of academic impact, for papers by Ann Morgan Breakdown of academic impact, for papers by Nancy A. Morgan Breakdown of academic impact, for papers by Paul Cascagnette Breakdown of academic impact, for papers by Susan Collier Breakdown of academic impact, for papers by Francisco Javier Cabrera Breakdown of academic impact, for papers by Melissa Clarke Breakdown of academic impact, for papers by Frank Barnhart Breakdown of academic impact, for papers by Lucy Frith
Rankless by CCL
2026